3 Other information

3.1 Scope and how this guideline was developed

NICE guidelines are developed in accordance with a scope that defines what the guideline will and will not cover.

Groups that will be covered

  • Men referred from primary care for investigation of possible prostate cancer, in line with Referral guidelines for suspected cancer (NICE clinical guideline 27).

  • Men with a biopsy-proven diagnosis of primary adenocarcinoma of the prostate, or an agreed clinical diagnosis[8] if biopsy is inappropriate.

  • Consideration will be given to men of African-Caribbean family origin.

Groups that will not be covered

  • Asymptomatic men with an abnormal PSA level detected in primary care who are not referred for subsequent investigation.

  • Men with metastatic disease of different primary origin involving the prostate.

  • Men with rare malignant tumours of the prostate, such as small cell carcinoma and rhabdomyosarcoma.

How this guideline was developed

NICE commissioned the National Collaborating Centre for Cancer to develop this guideline. The Centre established a Guideline Development Group (see section 4), which reviewed the evidence and developed the recommendations.

The methods and processes for developing NICE clinical guidelines are described in The guidelines manual.

3.2 Related NICE guidance

Details are correct at the time of publication (January 2014). Further information is available on the NICE website.

Published

General
Condition-specific

Under development

NICE is developing the following guidance (details available from the NICE website):

  • Prostate cancer (hormone relapsed, metastatic) – enzalutamide (after docetaxel). NICE technology appraisal guidance. Publication expected February 2014.

  • Prostate cancer (hormone relapsed, bone metastases) – radium-223 dichloride. NICE technology appraisal guidance. Publication expected February 2014.

  • Prostate cancer (metastatic, hormone relapsed) – sipuleucel-T (first line). NICE technology appraisal guidance. Publication expected February 2014.

  • Prostate cancer (advanced, hormone dependent) – degarelix depot. NICE technology appraisal guidance. Publication expected May 2014.

  • Suspected cancer. NICE clinical guideline. Publication date to be confirmed.



[8] Agreed clinical diagnosis on the basis of, for example, digital rectal examination, high PSA levels and known metastases.

  • National Institute for Health and Care Excellence (NICE)